Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

NEW INDICATIONS

Tecentriq First Immunotherapy FDA Approved for Adjuvant Treatment of Early-Stage Non–Small-Cell Lung Cancer

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On October 15, 2021, the FDA accelerated the approval of a new indication for atezolizumab (Tecentriq; Genentech), for the adjuvant treatment, after resection and platinum-based chemotherapy, of patients with stage II-IIIA non–small-cell lung cancer (NSCLC) and PD-L1 expression ≥1%, as determined by an FDA-approved test.

Atezolizumab is the first immunotherapy to receive FDA approval for the adjuvant treatment of early-stage (stage II-IIIA) NSCLC. This approval was based on recent results from the phase 3 IMpower010 clinical trial.

Simultaneously, the FDA also approved the VENTANA PD-L1 Assay (Ventana Medical Systems) as a companion diagnostic test to identify appropriate patients with NSCLC for adjuvant treatment with atezolizumab.

“Too many patients with early-stage lung cancer experience disease recurrence following surgery. Now, the availability of immunotherapy following surgery and chemotherapy offers many patients new hope and a powerful new tool to reduce their risk of cancer relapse,” said Bonnie Addario, Co-Founder and Chair, GO2 Foundation for Lung Cancer. “With this approval, it is more important than ever to screen for lung cancer early and test for PD-L1 at diagnosis to help bring this advance to the people who can benefit.”

The major efficacy outcome was disease-free survival (DFS), as assessed by the investigator in the primary efficacy analysis population. The study included 476 patients with stage II-IIIA NSCLC and PD-L1 expression ≥1% who received atezolizumab or best supportive care.

The median DFS was not reached (95% confidence interval [CI], 36.1-not estimable [NE]) in the atezolizumab arm versus 35.3 months (95% CI, 29.0-NE) in patients in the best supportive care arm (hazard ratio, 0.66; 95% CI, 0.50-0.88; P = .004).

In a prespecified secondary subgroup analysis of patients with stage II-IIIA NSCLC and PD-L1 expression ≥50%, the hazard ratio for DFS was 0.43 (95% CI, 0.27- 0.68). And in an exploratory subgroup analysis of patients with stage II-IIIA NSCLC and PD-L1 expression of 1% to 49%, the hazard ratio for DFS was 0.87 (95% CI, 0.60-1.26).

The most common (≥10%) adverse reactions (including laboratory abnormalities) with atezolizumab in this study were increased aspartate aminotransferase, blood creatinine, and alanine aminotransferase; hyperkalemia, rash, cough, hypothyroidism, pyrexia, fatigue/asthenia, musculoskeletal pain, peripheral neuropathy, arthralgia, and pruritus.

Related Items
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.